Neutralization of interleukin-2 retards the growth of mouse renal cancer

BJU International

Volumn 97, Issue 6, 2006, Pages 1314-1321

  Fukuhara, Hiroshi ^a   Matsumoto, Akihiko ^a   Kitamura, Tadaichi ^a   Takeuchi, Takumi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

CD25; Interleukin 2; Mouse; Renal cancer; T cells; Tumour immunity

Indexed keywords

BASILIXIMAB; CYTOKINE ANTIBODY; INTERLEUKIN 2; MONOCLONAL ANTIBODY; RECOMBINANT INTERLEUKIN 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNOLOGY; CARCINOMA CELL; CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL TRANSFER; CONTROLLED STUDY; IMMUNOREGULATION; INOCULATION; KIDNEY CANCER; LYMPHOCYTIC INFILTRATION; MALE; MOUSE; MOUSE STRAIN; NATURAL KILLER CELL; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; SPLEEN CELL; THYMUS;

ANIMALS; CARCINOMA, RENAL CELL; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; INTERLEUKIN-2; KIDNEY NEOPLASMS; KILLER CELLS, NATURAL; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; RECEPTORS, INTERLEUKIN-2;

EID: 33745206906     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2006.06180.x     Document Type: Article

References (15)

1. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995 155: 1151 64
2. Onizuka S, Tawara I, Shimizu J, Sakaguchi S, Fujita T, Nakayama E. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res 1999 59: 3128 33
3. + T cells: a common basis between tumor immunity and autoimmunity. J Immunol 1999 163: 5211 8
4. Takeuchi T, Konno-Takahashi N, Kasuya Y, Ogushi T, Nishimatsu H, Kitamura T. Interleukin-2 blocks the antitumour activity caused by depletion of CD25 cells in a murine renal adenocarcinoma model. BJU Int 2004 94: 171 6
5. Sakaguchi S, Fukuma K, Kuribayashi K, Masuda T. Organ-specific autoimmune diseases induced in mice by elimination of T cell subset. I. Evidence for the active participation of T cells in natural self-tolerance; deficit of a T cell subset as a possible cause of autoimmune disease. J Exp Med 1985 161: 72 87
6. Papiernik M, de Moraes ML, Pontoux C, Vasseur F, Penit C. Regulatory CD4 T cells: expression of IL-2Rα chain, resistance to clonal deletion and IL-2 dependency. Int Immunol 1998 10: 371 8
7. Thornton AM, Shevach EM. CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med 1998 188: 287 96
8. Sadlack B, Merz H, Schorle H, Schimpl A, Feller AC, Horak I. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 1993 75: 253 61
9. Sadlack B, Lohler J, Schorle H et al. Generalized autoimmune disease in interleukin-2-deficient mice is triggered by an uncontrolled activation and proliferation of CD4+ T cells. Eur J Immunol 1995 25: 3053 9
10. Sadlack B, Kuhn R, Schorle H, Rajewsky K, Muller W, Horak I. Development and proliferation of lymphocytes in mice deficient for both interleukins-2 and -4. Eur J Immunol 1994 24: 281 4
11. Coligan TJ, Kruisbeek AM, Margulies DH, Shevach EM, Strober W eds, Current Protocol in Immunology. Hoboken: Wiley Interscience, 1991: 3.1.1 3. 1.5
12. Takeuchi T, Ueki T, Sasaki Y et al. Th2-like response and antitumor effect of anti-interleukin-4 mAb in mice bearing renal cell carcinoma. Cancer Immunol Immunother 1997 43: 375 81
13. Klebb G, Autenrieth IB, Haber H et al. Interleukin-2 is indispensable for development of immunological self-tolerance. Clin Immunol Immunopathol 1996 81: 282 6
14. Setoguchi R, Hori S, Takahashi T, Sakaguchi S. Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J Exp Med 2005 201: 723 35
15. Negrier S, Escudier B, Lasset C et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie. N Engl J Med 1998 338: 1272 8